GlassScriptPhysician profile
Jeffrey Wagner
NPI 1881684207
$6,965.53
in general payments reported to CMS, 2019-2025
23 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $1,450 · 2021: $1,009 · 2022: $819 · 2023: $1,228 · 2024: $978 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.38 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,322.99 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,158.40 | 2019-2025 | |
| Biocryst Pharmaceuticals, INC. | $897.39 | 2020 | |
| Glaxosmithkline, LLC. | $675.41 | 2019-2024 | Nucala |
| Abbvie INC. | $251.86 | 2022-2023 | Rinvoq |
| Biocryst US Sales Co., LLC | $243.85 | 2021-2025 | Orladeyo |
| Csl Behring | $223.95 | 2019-2022 | |
| Alk-Abello, INC | $208.57 | 2019-2021 | |
| Amgen INC. | $183.24 | 2023 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $143.57 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $115.51 | 2022-2023 | Dupixent |
| Pfizer INC. | $93.07 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $79.25 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $74.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $66.27 | 2019-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $62.10 | 2019-2021 | |
| Incyte Corporation | $46.74 | 2023-2024 | Opzelura |
| Kaleo, INC. | $37.74 | 2019-2024 | Auvi-Q |
| Horizon Therapeutics Plc | $24.01 | 2020 | |
| Verona Pharma, INC. | $16.50 | 2025 | Ohtuvayre |
| Hikma Pharmaceuticals USA | $14.94 | 2024 | Ryaltris |
| Mylan Specialty L.P. | $13.06 | 2021 | |
| Shire North American Group INC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.